CLDN8 antibody - C-terminal region (ARP33621_T100)
- Known as:
- CLDN8 (anti-) - C-terminal region (ARP33621_T100)
- Catalog number:
- arp33621_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- CLDN8 antibody - C-terminal region (ARP33621_T100)
Related genes to: CLDN8 antibody - C-terminal region (ARP33621_T100)
- Gene:
- CLDN8 NIH gene
- Name:
- claudin 8
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 21q22.11
- Locus Type:
- gene with protein product
- Date approved:
- 1998-11-19
- Date modifiied:
- 2016-10-05
Related products to: CLDN8 antibody - C-terminal region (ARP33621_T100)
Related articles to: CLDN8 antibody - C-terminal region (ARP33621_T100)
- Impaired airway epithelial barrier function is a pathogenic driver in a subset of individuals with asthma. MicroRNAs, small RNAs that function as post-transcriptional regulators of gene expression, may be involved in the regulation of the airway epithelial barrier. This study aimed to determine if microRNAs cause epithelial barrier dysfunction through the targeting of mRNAs involved in maintaining airway epithelial barrier integrity. - Source: PubMed
Publication date: 2026/01/16
Lässer CeciliaAx ElisabethWeidner JulieWinslow SofiaIngelhag HannesCalvén JennyMalmhäll CarinaJevnikar ZalaOlsson HenricRådinger Madeleine - Drought and water scarcity, exacerbated by global warming, are enormous threats to global food sustainability and security. Poultry, in particular, are highly impacted by adverse environmental stressors. As nutrient absorption and intestinal integrity are critical for growth and performance, understanding the impact on the broiler gastrointestinal tract is highly relevant. Here, we examined the effect of chronic cyclic heat stress (HS) on the jejunal expression profile of tight-junction, gap-junction, adherens, and desmosome genes in the 4th generation of broiler lines divergently selected for low (LWE)- and high-water efficiency (HWE). Male HWE and LWE broilers (n = 240/line) were allotted to 12 environmental chambers (2 floor pens/chamber, 6 chambers/line, 20 birds/pen) and were exposed to cyclic HS (36°C for 9h/day from 9:00 am to 6:00 pm) or thermoneutral conditions (25°C) from day 29 to 49 of age in a 2 × 2 factorial design. Growth performance and mortality were recorded. At day 49, jejunal tissues were collected for molecular analyses using real-time quantitative PCR and immunoblot. Jejunal gene expression of multiple gut integrity factors were higher (P < 0.05) in the HWE as compared to the LWE lines, including claudin 22 (CLDN22), -34, occluding (OCDN), zona-occludin-2 (ZO-2), gap junction alpha1 (GJA1), GJA3, GJC1, and cadherin 1 (CDH1). CLDN8, -20, -25, -4, GJC2, and GJD2 were also greater (P < 0.05) in HWE, but were additionally downregulated (P < 0.05) during HS. Conversely PALS1-associated tight junction protein (PATJ) and desmocollin 1 (DSC1) mRNAs were significantly downregulated in the HWE as compared to the LWE broilers. Significant interactions between the line and environment were seen in CLDN1, where the expression was decreased in the LWE but increased in the HWE in HS. Additionally, CLDN15 and -16 genes were greatest in the HWE under TN conditions, while catenin alpha 2 (CTNNA2) was highest in the HWE during HS. Overall, the jejunal expression profile of key genes associated with intestinal barrier integrity likely contributes to the water efficiency phenotype and the response of these birds to HS. - Source: PubMed
Publication date: 2025/12/16
Greene Elizabeth SOrlowski SaraDridi Sami - Crohn's disease (CD) and psoriasis are both chronic inflammatory diseases. However, the exact molecular interplay remains incompletely elucidated. This study aimed to identify shared molecular markers and functional pathways underlying both diseases and explore their correlations with immune infiltration. - Source: PubMed
Publication date: 2025/11/08
Zhang MinnaWei YueYang BoWang HonggangDai WeijieYang Xiaozhong - Breast cancer is a heterogeneous disease, and treatment resistance remains a critical challenge. Claudin-8 (CLDN8), a tight junction protein, has emerged as a potential indicator of therapeutic response and prognosis in breast cancer patients. In this study, we evaluated CLDN8 as a predictive biomarker and a potential therapeutic target. We analyzed CLDN8 gene expression in breast cancer patient cohorts to assess its association with clinical outcomes and response to therapy. We also established breast cancer cell models with altered CLDN8 expression to examine its effects on cell behavior and drug sensitivity. High CLDN8 expression was significantly associated with improved disease-free survival, particularly in estrogen receptor-negative patients ( = 0.007), suggesting a favorable prognostic role. Notably, tumors with elevated CLDN8 showed better outcomes in patients treated with surgery alone or endocrine therapy, whereas in those receiving chemotherapy (including neoadjuvant) or anti-HER2 therapy, high CLDN8 levels were paradoxically linked to poorer survival and therapy resistance. In vitro, CLDN8 knockdown reduced sensitivity to endocrine treatments, HER2-targeted agents, and chemotherapeutic drugs, mirroring clinical patterns. In conclusion, our findings identify CLDN8 as an important prognostic factor in breast cancer and as a novel predictor of treatment response. These results underscore the potential utility of CLDN8 status in guiding personalized therapy and highlight CLDN8 as a candidate target for overcoming treatment resistance in breast cancer. - Source: PubMed
Publication date: 2025/06/05
Ji WenxiaoLou YufeiJiang Wen GRuge FionaMartin Tracey A - Despite the extensive use of biomarkers like PSA, AMACR, and PCA3, prostate cancer (PCa) is still a major clinical challenge, demanding the development of more precise and specific methods for diagnosis. In this study, a deep learning model was applied to identify ten key genes from a pool of 68 common differentially expressed genes in the three transcriptomic datasets. The model demonstrated high performance, with the accuracy of 0.969, R of 0.88, and PR-AUC of 0.98. Notably, selected genes have been previously reported as functionally important in various cancers. Among them, SCUBE2 stands out as a novel potential diagnostic biomarker in prostate cancer, showing a strong diagnostic performance in the TCGA dataset with AUC = 0.84, sensitivity = 0.76, and specificity = 0.84. SCUBE2 is a secreted glycoprotein known for its ability to suppress tumor growth, cell migration, and epithelial-mesenchymal transition (EMT) in several cancer types, including gliomas, breast, and colorectal cancers, mainly through its regulation of signaling pathways such as Hedgehog (Shh). Although its role in prostate cancer (PCa) has not been previously explored, its consistent downregulation across multiple PCa datasets in this study suggests it may act as a tumor suppressor, warranting further investigation. Another candidate, SLC16A5, showed moderate performance individually (AUC = 0.62, SP = 0.81, SE = 0.42 in GSE88808), but its combination with SCUBE2 significantly enhanced diagnostic accuracy (combined AUC = 0.76, SE = 0.75, SP = 0.71). SLC16A5 is a monocarboxylate transporter involved in metabolic reprogramming, and prior studies have linked its downregulation to immune infiltration and poor prognosis in PCa. Functional enrichment analysis of the ten identified genes revealed strong involvement of these genes in cancer-related processes, including gap junction assembly, tight junction formation, efflux transporter activity, and pathways such as Hedgehog signaling, leukocyte transendothelial migration, and cell-cell adhesion. Hub gene analysis further confirmed the central roles of identified genes such as CAV1, GJA1, AMACR, and CLDN8, which are well-documented in cancer progression, metastasis, or therapeutic resistance. In summary, this study identifies SCUBE2 as a novel potential diagnostic biomarker for prostate cancer and supports the use of AI-driven gene discovery in identifying key players in tumor biology. The combination of SCUBE2 with SLC16A5 not only enhances diagnostic precision but also opens new avenues for functional and clinical validation, ultimately contributing to the development of more accurate, multi-gene diagnostic panels for PCa. - Source: PubMed
Publication date: 2025/05/08
Khorshid Sokhangouy SaeidehZeinali MohsenFathi SinaNazari Elham